Product Details
Mysimba is an effective weight loss medication used for the management of weight in adults over the age of 18 with a body mass index (BMI) of over 30, or over 27 if weight-related co-morbidities such as type 2 diabetes or controlled hypertension are a factor.
There are many reasons why people gain weight. Some of the most common among them include excessive hunger, difficulty managing portion sizes and stress or anxiety-related eating. Mysimba can help adults struggling with obesity to lose their excess weight quickly, effectively and safely.
Mysimba is a medication that can help you manage your weight. It contains two active ingredients, naltrexone and bupropion, which work together to reduce your appetite and food cravings. This medication is suitable for adults who are overweight or obese and have not been able to lose weight through diet and exercise alone.
- Weight-loss medicine
- BMI of 27 kg/m² or greater
- Avoid drinking alcohol while taking this medicine
- Can cause dizziness
What Is Mysimba And How Is It Utilized
Mysimba is recommended for the control of weight in adult patients (≥18 years) with a baseline Body Mass Index (BMI) of
- ≥ 30 kg/m2 (obese), or
- ≥ 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of one or more weight-related co morbidities (e.g., type 2 diabetes, dyslipidaemia, or controlled hypertension).
After 16 weeks, individuals who have not dropped at least 5% of their starting body weight should stop using the product.
What Is The Use Of Mysimba
This medication is only accessible with a prescription and comes as prolonged-release pills that include 78 mg of bupropion and 7.2 mg of naltrexone. Naltrexone and bupropion are released gradually from the tablet over several hours when it is prolonged-release.
Treatment begins with a single tablet taken every morning. Over the course of four weeks, the dosage is progressively increased to the recommended two pills taken twice daily, ideally with meals.
Patients who experience particular adverse effects, such elevated blood pressure, should have their reaction and tolerability to the medication monitored on a frequent basis. If patients have not lost at least 5% of their starting body weight after four months of treatment, the medication should also be discontinued.
How Does Mysimba Function
The two active ingredients, naltrexone and bupropion, act on the areas of the brain that regulate energy balance and food intake while also lessening the impact of the area of the brain that regulates the enjoyment of eating. The precise mechanism of action of this medication is still unclear. When combined, their effects decrease desire and food intake while increasing energy expenditure, which helps patients maintain a calorie-restricted diet and lose weight.
What Advantages Of Mysimba Have Been Demonstrated By Research
This medication was compared with a placebo (a dummy medication) in four major studies with over 4,500 obese or overweight patients to demonstrate the effectiveness of the medication in lowering body weight.
Process
The medication was administered to study participants as part of a weight-loss regimen that included counseling and dietary and exercise recommendations. The percentage of patients who lost at least 5% of their body weight during the course of 28 or 56 weeks of treatment served as the primary indicators of efficacy.
Results
The results were analyzed using a variety of techniques to account for the percentage of patients who did not finish the tests (about 50% over a year), and the research also examined the number of individuals who achieved at least a stricter 10% reduction in weight.
In three of the inquiries, Mysimba-treated patients lost an average of 3.7 to 5.7% of their body weight compared to 1.3 to 1.9% with a placebo; the percentage of Mysimba-treated patients who lost 5% of their body weight varied from 28 to 42% compared to 12 to 14% with a placebo. Mysimba users reduced their weight by at least 10% in 13–22% of cases, compared to 5–6% of patients receiving a placebo.
The overall weight reduction over the research period was higher in the other study, which also involved more intense patient counseling: 8.1% with Mysimba and 4.9% with placebo. Mysimba-treated patients lost 5% and 10% of their body weight, respectively, compared to 34% and 17% of patients who received a placebo.
Conclusion
Adopting various analytical techniques, the degree of improvement with Mysimba over placebo was comparable; however, the benefits were minimal when adopting the most conservative techniques, which presumed that patients who did not finish the study would not have seen any improvement. Patients who finished 56 weeks of treatment or who had reduced at least 5% of their initial body weight by four months showed a more pronounced treatment impact.
What Are The Risks Associated With Mysimba
Constipation and nausea and vomiting (feeling of being sick) are the most frequent adverse effects, which may affect more than 1 in 10 patients; dizziness and dry mouth were also common (found in up to 1 patient in 10.
This medication should not be administered to patients who have a high risk of adverse effects, such as those with severely impaired kidney or liver function, uncontrolled hypertension, a history of seizures (fits), certain psychological issues, a brain tumor, or withdrawal from alcohol or certain medications. See the package brochure for the complete list of limitations.
Why Is Mysimba Accepted By Society
The Agency’s Committee for Medicinal Products for Human Use (CHMP) determined that, despite the medication’s limited effectiveness in promoting weight loss, it was sufficient to be clinically significant. Mandatory treatment reevaluation after four months should guarantee that the medication is only continued in patients who benefit from it.
In terms of safety, the most frequent side effects were mostly controllable because patients could stop taking the medication if they were bothersome, despite some worries about potential effects on the heart and blood vessels (cardiovascular outcomes) and a slightly increased risk of seizures (fits).
While the CHMP also suggested continued monitoring of the medication’s cardiovascular effects, interim data from an ongoing study of cardiovascular outcomes were examined during the assessment.The CHMP recommended that Mysimba be authorized after concluding that the benefits outweigh the risks based on the available data.
What Steps Are Being Taken To Guarantee Mysimba’s Safe & Efficient Use?
To make sure the medication is utilized as safely as possible, a risk management strategy has been created. The package leaflet and summary of product features contain safety information based on this plan, including the proper safety measures that patients and healthcare providers should take.
Additionally, Mysimba marketing business will create an information pack for physicians who prescribe the medication, which will include instructions on how to discontinue therapy in individuals who do not respond or if adverse effects are a problem. Additionally, it will conduct additional research to evaluate the medication’s impact on the heart and blood arteries.
